FDA Revises Generic Peptide Guidance: What the 17 Drafts Cover

FDA did not approve 17 generic peptide drugs on July 28, 2026. It published 17 revised draft product-specific guidances, or PSGs, that recommend how developers may assemble abbreviated new drug applications for particular peptide products. The difference matters: a draft guidance describes an agency approach; an approval follows review of an actual application and its supporting data.

The FDA announcement groups the revisions around five scientific themes: production route, innate immune response testing, impurity thresholds, higher-order structure, and biological activity. Those subjects reflect why a peptide generic can require more than a simple check of chemical formula and amount.

The 17 drafts, organized by peptide

Seventeen documents do not mean 17 different active ingredients. Several peptides have separate PSGs because they refer to different listed drugs, dosage forms, or reference applications.

Peptide product	Reference products named by FDA	Drafts
Calcitonin salmon	Calcimar; Miacalcin	2
Dasiglucagon hydrochloride	Zegalogue	1
Glucagon	Baqsimi; Glucagon; Gvoke	3
Liraglutide	Victoza; Saxenda	2
Pegcetacoplan	Syfovre; Empaveli	2
Semaglutide	Ozempic; Wegovy	2
Teriparatide	Forteo; Teriparatide	2
Tirzepatide	Mounjaro; Zepbound	2
Vosoritide	Voxzogo	1

That count reaches 17 across nine peptide groups. It includes medicines associated with diabetes and obesity care, osteoporosis, macular degeneration, and other uses. The list should not be read as a new indication list or prescribing update. Each PSG is tied to generic development for the relevant reference product.

The separate semaglutide and tirzepatide entries are also a useful reminder that a molecule’s brand context matters. A reader looking for a neutral description of the molecules can use the Jacked Forums references for semaglutide and tirzepatide. The PSG announcement, however, is about the evidence FDA expects in an ANDA—not how an individual should use either medicine.

What a product-specific guidance actually does

An ANDA relies on FDA’s prior finding for an approved reference drug rather than repeating the full development program used for a new drug application. The generic applicant still has to meet applicable requirements, including showing that its proposed product is sufficiently comparable to the reference product and that it can be made to the required quality standard.

A PSG narrows that broad job into recommendations for one product. It can tell a developer which studies, analytical comparisons, or other evidence FDA currently considers appropriate. This can make expectations clearer before an application reaches the review queue and reduce avoidable rounds of questions.

It does not pre-judge the application. A company could follow a draft recommendation and still submit incomplete, unreliable, or unacceptable evidence. Conversely, guidance documents generally describe recommendations rather than creating a binding route that eliminates scientific judgment. FDA says developers considering whether the recommendations may apply to other peptide products should contact the Office of Generic Drugs through a formal meeting request or controlled correspondence.

Why the five technical themes matter

The first theme is production route. FDA says the drafts address submission of recombinantly, synthetically, or semi-synthetically produced peptides as ANDAs. Two products with the same intended peptide sequence may reach it through different processes, and those processes can leave different impurities or structural features that need to be understood.

The other four themes ask whether the proposed product has been characterized closely enough:

• Innate immune response testing examines whether product attributes may trigger an early immune response.
• Impurity thresholds address what related substances are present and at what levels, not merely whether the main peptide is detectable.
• Higher-order structure assessment looks beyond the primary amino-acid sequence to the molecule’s three-dimensional organization.
• Biological activity assessment tests whether the proposed product performs the relevant biological function comparably, rather than treating identity on paper as the whole case.

The announcement does not supply one universal test battery for every peptide. It points to updated product-specific recommendations across those areas. That distinction keeps the five themes from being turned into a homemade checklist divorced from the actual PSG for a reference product.

Draft, final, and approved are three different states

FDA states that the PSGs are revised drafts. The agency will consider comments submitted to the public docket, and the documents will represent FDA’s current thinking when finalized. At the accessed date, that future-tense language was still important.

Three statements can therefore be true at once:

1. FDA has publicly described an updated scientific approach.
2. The 17 documents remain draft recommendations subject to comment and revision.
3. No generic product receives approval merely because a PSG exists for it.

The announcement also says FDA withdrew its May 2021 industry guidance, ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin, because it no longer reflected the agency’s current scientific thinking. Withdrawal of that older document is a guidance-management action. It is not a recall of a drug, cancellation of existing approvals, or judgment that every application developed under earlier thinking is defective.

How to read the update without overreading it

For developers, the useful question is which revised PSG applies to a proposed ANDA and what evidence that document recommends. For everyone else, the main signal is that FDA is updating how it evaluates increasingly complex generic peptide products, including products made through different technical routes.

The announcement does not change a prescription, authorize compounding, validate an online product, or establish that an unapproved vial is equivalent to an approved medicine. It also should not be merged with unrelated regulatory actions. FDA’s GLP-1 bulk-substance import alert concerns supply-chain enforcement, while Europe’s oral Wegovy decision concerns authorization of a finished product. The 17 PSGs occupy a third lane: recommendations for the development and review of potential U.S. generics.

That lane is consequential without being an approval headline. FDA has made its developing scientific expectations more visible; applicants still have to generate product-specific evidence, submit it, and pass review.